Talis Biomedical Statistics Share Statistics Talis Biomedical has 1.82M
shares outstanding. The number of shares has increased by 0.04%
in one year.
Shares Outstanding 1.82M Shares Change (YoY) 0.04% Shares Change (QoQ) 0% Owned by Institutions (%) 0.83% Shares Floating 1.16M Failed to Deliver (FTD) Shares 2 FTD / Avg. Volume 0.14%
Short Selling Information The latest short interest is 17.96K, so undefined% of the outstanding
shares have been sold short.
Short Interest 17.96K Short % of Shares Out n/a Short % of Float 2.35% Short Ratio (days to cover) 0.59
Valuation Ratios The PE ratio is -0.22 and the forward
PE ratio is -0.07.
Talis Biomedical's PEG ratio is
0.
PE Ratio -0.22 Forward PE -0.07 PS Ratio 32.87 Forward PS 0.2 PB Ratio 0.2 P/FCF Ratio -0.25 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Talis Biomedical.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.86,
with a Debt / Equity ratio of 0.28.
Current Ratio 8.86 Quick Ratio 8.86 Debt / Equity 0.28 Debt / EBITDA -0.3 Debt / FCF -0.37 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $4.16K Profits Per Employee $-626.33K Employee Count 99 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -79.36% in the
last 52 weeks. The beta is 1.47, so Talis Biomedical's
price volatility has been higher than the market average.
Beta 1.47 52-Week Price Change -79.36% 50-Day Moving Average 1.67 200-Day Moving Average 3.2 Relative Strength Index (RSI) 61.64 Average Volume (20 Days) 1,411
Income Statement In the last 12 months, Talis Biomedical had revenue of 412K
and earned -62.01M
in profits. Earnings per share was -34.12.
Revenue 412K Gross Profit 371K Operating Income -66.81M Net Income -62.01M EBITDA -66.05M EBIT -66.81M Earnings Per Share (EPS) -34.12
Full Income Statement Balance Sheet The company has 76.73M in cash and 19.67M in
debt, giving a net cash position of 57.06M.
Cash & Cash Equivalents 76.73M Total Debt 19.67M Net Cash 57.06M Retained Earnings -539.96M Total Assets 72.7M Working Capital 55.41M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -53.24M
and capital expenditures -486K, giving a free cash flow of -53.73M.
Operating Cash Flow -53.24M Capital Expenditures -486K Free Cash Flow -53.73M FCF Per Share -29.56
Full Cash Flow Statement Margins Gross margin is 90.05%, with operating and profit margins of -16217.23% and -15050.24%.
Gross Margin 90.05% Operating Margin -16217.23% Pretax Margin -15050.24% Profit Margin -15050.24% EBITDA Margin -16030.34% EBIT Margin -16217.23% FCF Margin -13040.29%
Dividends & Yields TLIS does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for TLIS.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 6, 2023. It was a
backward
split with a ratio of 1:15.
Last Split Date Jul 6, 2023 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -12.33 Piotroski F-Score 1
